AR019947A1 - Metodo para tratar o prevenir trastornos causados por disfunciones de la motilidad intestinal en seres humanos y composiciones farmaceuticas de aplicacionen dicho metodo - Google Patents

Metodo para tratar o prevenir trastornos causados por disfunciones de la motilidad intestinal en seres humanos y composiciones farmaceuticas de aplicacionen dicho metodo

Info

Publication number
AR019947A1
AR019947A1 ARP990103729A ARP990103729A AR019947A1 AR 019947 A1 AR019947 A1 AR 019947A1 AR P990103729 A ARP990103729 A AR P990103729A AR P990103729 A ARP990103729 A AR P990103729A AR 019947 A1 AR019947 A1 AR 019947A1
Authority
AR
Argentina
Prior art keywords
dysfunctions
treat
applying
pharmaceutical compositions
human beings
Prior art date
Application number
ARP990103729A
Other languages
English (en)
Original Assignee
Sepracor Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sepracor Inc filed Critical Sepracor Inc
Publication of AR019947A1 publication Critical patent/AR019947A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4468—Non condensed piperidines, e.g. piperocaine having a nitrogen directly attached in position 4, e.g. clebopride, fentanyl
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/06—Anti-spasmodics, e.g. drugs for colics, esophagic dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/10—Laxatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/14—Prodigestives, e.g. acids, enzymes, appetite stimulants, antidyspeptics, tonics, antiflatulents

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Nutrition Science (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Hydrogenated Pyridines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

Se trata de composiciones que emplean métodos donde se utilizan el isomero de norcisaprida puro (+). Se ha hallado sorprendentemente que este compuestoresulta ser una droga potente para el tratamiento de trastornos del sistema nervioso central. Seha hallado también que el compuesto, norcisaprida (+) resultaser un potente agente antiemético. Finalmente, el isomero de norcisaprida (+) evita también ciertos efectos secundarios adversos y ciertas interacciones dedroga adversas.
ARP990103729A 1998-07-28 1999-07-28 Metodo para tratar o prevenir trastornos causados por disfunciones de la motilidad intestinal en seres humanos y composiciones farmaceuticas de aplicacionen dicho metodo AR019947A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US09/123,892 US6147093A (en) 1996-07-19 1998-07-28 Methods for treating gastroesophageal reflux disease

Publications (1)

Publication Number Publication Date
AR019947A1 true AR019947A1 (es) 2002-03-27

Family

ID=22411520

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP990103729A AR019947A1 (es) 1998-07-28 1999-07-28 Metodo para tratar o prevenir trastornos causados por disfunciones de la motilidad intestinal en seres humanos y composiciones farmaceuticas de aplicacionen dicho metodo

Country Status (25)

Country Link
US (4) US6147093A (es)
EP (1) EP1100502A1 (es)
JP (1) JP2002521448A (es)
KR (1) KR20010071047A (es)
CN (1) CN1320036A (es)
AR (1) AR019947A1 (es)
AU (1) AU5126099A (es)
BG (1) BG105218A (es)
BR (1) BR9912581A (es)
CA (1) CA2338465A1 (es)
CO (1) CO5060499A1 (es)
CZ (1) CZ295776B6 (es)
EA (1) EA200100188A1 (es)
EE (1) EE200100051A (es)
HK (1) HK1041226A1 (es)
HR (1) HRP20010075A2 (es)
HU (1) HUP0102979A3 (es)
ID (1) ID28894A (es)
IL (1) IL141047A0 (es)
NO (1) NO20010464L (es)
NZ (1) NZ509671A (es)
PL (1) PL345764A1 (es)
SK (1) SK1202001A3 (es)
TR (1) TR200100921T2 (es)
WO (1) WO2000006165A1 (es)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6147093A (en) * 1996-07-19 2000-11-14 Sepracor Inc. Methods for treating gastroesophageal reflux disease
BR9811676A (pt) * 1997-07-11 2000-09-19 Janssen Pharmaceutica Nv (+) norcisaprida útil para distúrbios mediados por 5-ht3 e 5-ht4
US6353005B1 (en) 1999-03-02 2002-03-05 Sepracor, Inc. Method and compositions using (+) norcisapride in combination with proton pump inhibitors or H2 receptor antagonist
DE10314916A1 (de) 2003-04-01 2004-10-21 Endress + Hauser Flowtec Ag, Reinach Vorrichtung zur Bestimmung und/oder Überwachung des Volumen- und/oder Massenstroms eines Mediums
JP4740152B2 (ja) * 2003-12-23 2011-08-03 セロドス アクスイェ セルスカブ 末梢性５−ｈｔ受容体の修飾因子
US8524736B2 (en) 2004-01-07 2013-09-03 Armetheon, Inc. Stereoisomeric compounds and methods for the treatment of gastrointestinal and central nervous system disorders
DK2194053T3 (da) 2004-01-07 2013-07-01 Armetheon Inc Methoxypiperidinderivater til brug i behandling af gastrointestinale forstyrrelser og forstyrrelser i centralnervesystemet.
US8138204B2 (en) * 2004-01-07 2012-03-20 Aryx Therapeutics, Inc. Stereoisomeric compounds and methods for the treatment of gastrointestinal and central nervous system disorders
US20050160544A1 (en) * 2004-01-26 2005-07-28 Marc Geller Contoured grill brush
CA2620379C (en) * 2005-08-31 2015-02-24 Aryx Therapeutics, Inc. Synthetic methods and intermediates for stereoisomeric compounds useful for the treatment of gastrointestinal and central nervous system disorders
WO2007149929A1 (en) * 2006-06-23 2007-12-27 Aryx Therapeutics, Inc. Piperidine derivatives for the treatment of gastrointestinal and cns disorders
US10570127B1 (en) 2018-11-05 2020-02-25 Renexxion, Llc Material and methods for the treatment of gastro-intestinal disorders

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5057525A (en) * 1981-10-01 1991-10-15 Janssen Pharmaceutica N.V. Novel N-(3-hydroxy-4-piperidinyl) benzamide derivatives
US4962115A (en) * 1981-10-01 1990-10-09 Janssen Pharmaceutica N.V. Novel N-(3-hydroxy-4-piperidinyl)benzamide derivatives
US5137896A (en) * 1981-10-01 1992-08-11 Janssen Pharmaceutica N.V. N-(3-hydroxy-4-piperidinyl)benzamide derivatives
AU4770593A (en) * 1992-07-07 1994-01-31 Sepracor, Inc. Methods of using (+) cisapride for the treatment of gastro-esophageal reflux disease and other disorders
JPH08502032A (ja) * 1992-07-07 1996-03-05 セプラコア インコーポレーテッド 胃食道逆流疾患およびその他の障害を治療するために▲（−）▼シサプリドを使用する方法
AU7397194A (en) * 1993-07-06 1995-02-06 Mcneil-Ppc, Inc. H2 antagonist-gastrointestinal motility agent combinations
US5712293A (en) * 1995-06-07 1998-01-27 Sepracor, Inc. Methods for treating gastro-esophageal reflux disease and other disorders associated with the digestive tract using optically pure (-) norcisapride
US5739151A (en) * 1996-07-19 1998-04-14 Sepracor Inc. Method for treating emesis and central nervous system disorders using optically pure (+) norcisapride
US6147093A (en) * 1996-07-19 2000-11-14 Sepracor Inc. Methods for treating gastroesophageal reflux disease
BR9811676A (pt) * 1997-07-11 2000-09-19 Janssen Pharmaceutica Nv (+) norcisaprida útil para distúrbios mediados por 5-ht3 e 5-ht4

Also Published As

Publication number Publication date
CA2338465A1 (en) 2000-02-10
SK1202001A3 (en) 2001-08-06
EP1100502A1 (en) 2001-05-23
NZ509671A (en) 2003-08-29
JP2002521448A (ja) 2002-07-16
CO5060499A1 (es) 2001-07-30
HUP0102979A3 (en) 2002-01-28
CN1320036A (zh) 2001-10-31
HRP20010075A2 (en) 2002-02-28
BR9912581A (pt) 2001-05-02
AU5126099A (en) 2000-02-21
CZ2001348A3 (cs) 2002-01-16
WO2000006165A1 (en) 2000-02-10
US6632827B2 (en) 2003-10-14
NO20010464D0 (no) 2001-01-26
CZ295776B6 (cs) 2005-11-16
IL141047A0 (en) 2002-02-10
US20010020031A1 (en) 2001-09-06
ID28894A (id) 2001-07-12
HUP0102979A2 (hu) 2001-12-28
EA200100188A1 (ru) 2001-08-27
US6147093A (en) 2000-11-14
US6242465B1 (en) 2001-06-05
NO20010464L (no) 2001-03-23
HK1041226A1 (zh) 2002-07-05
EE200100051A (et) 2002-06-17
TR200100921T2 (tr) 2001-10-22
US20040044039A1 (en) 2004-03-04
KR20010071047A (ko) 2001-07-28
PL345764A1 (en) 2002-01-02
BG105218A (en) 2001-11-30

Similar Documents

Publication Publication Date Title
ES2145774T3 (es) Derivados de adenosina que tienen actividad agonista en a2.
AR026610A1 (es) Un derivado pirrolidinacetamida solo o en combinacion para tratamiento de desordenes del sistema nervioso central
AR019947A1 (es) Metodo para tratar o prevenir trastornos causados por disfunciones de la motilidad intestinal en seres humanos y composiciones farmaceuticas de aplicacionen dicho metodo
NO20030724L (no) Anvendelse av derivater av valproinsyreamider og 2- valproensyreamider for terapi eller prevensjon av smerte- og/eller hodepinelidelser
SV1998000029A (es) Compuestos de pirazina ref. pg3186
CR6210A (es) Composiciones de celecoxib
ES2151083T3 (es) Composiciones orales que contienen ondansetron.
ATE450269T1 (de) Peptid pyyä3-36ü zur behandlung von stoffwechselkrankheiten
PA8484301A1 (es) Formulaciones farmaceuticas de liberacion controlada
PE20040751A1 (es) COMPOSICION FARMACEUTICA QUE COMPRENDE DOSIS BAJAS DE UN INHIBIDOR DEL TNFalfa HUMANO
CO5160320A1 (es) Metodos y composiciones para la prevencion de tolerancia a medicamentos das.
UY26130A1 (es) Compuestos para tratar la obesidad
BR9708287A (pt) Processo para tratar ou prevenir um distúrbio do sistema nervoso central em um ser humano, para eliciar um efeito antiemético em um ser humano e para tratar um estado de doença em um ser humano, composição farmacêutica para tratar de distúrbios do sistema nervoso central em um ser humano, e, forma de dosagem unitária farmacêutica
DK1346041T3 (da) Terapeutiske midler og fremgangsmåder til anvendelse deraf til behandling af en amyloidogen sygdom
ES2176343T3 (es) Composiciones sanadoras de tratamiento de heridas causadas por el acne que contienen un piruvano, un antioxidante y una mezcla de acidos grasos.
AR008799A1 (es) Composicion de vacuna para prevenir o tratar el paludismo; uso de dicha composicion para elaborar medicamentos y metodo para dicha profilaxis y dichotratamiento
RU94002337A (ru) Фармацевтическая композиция, применение гамма-линоленовой или дигомо-гамма-линоленовой кислоты для лечения поражений после облучения, способ лечения
AR006401A1 (es) Compuestos de pirrolopirrolona, una composicion farmaceutica que los contiene, su uso en la fabricacion de un medicamento y en terapia, procesospara su preparación y compuestos intermediarios para dichos procesos.
ES2188582T3 (es) El uso de ranitidina-citrato de bismuto en combinacion con claritromicina o claritromicina y tetraciclina en la fabricacion de un medicamento para tratar trastornos gastrointestinales.
PA8457001A1 (es) Derivados del 2-(4-aril o heteroaril-piperazin-i-ilmetil)-1h-indol
MX163574B (es) Procedimiento para preparar una composicion farmaceutica para inhalacion conteniendo un gangliosido
DK1032556T3 (da) Farmaceutisk aktive forbindelser og anvendelsesfremgangsmåder
ECSP003707A (es) Diazepanes
RU94041028A (ru) Применение производных мелатонина для лечения десинхронизационных нарушений, фармацевтическая композиция
DE69429856D1 (de) Substituierte caprolactame und deren derivate verwendbar zur behandlung der hiv-krankheit

Legal Events

Date Code Title Description
FA Abandonment or withdrawal